vs
BioLineRx Ltd.（BLRX）与拜玛林制药（BMRN）财务数据对比。点击上方公司名可切换其他公司
拜玛林制药的季度营收约是BioLineRx Ltd.的2876.9倍（$874.6M vs $304.0K）。拜玛林制药净利率更高（-5.3% vs -1296.1%，领先1290.7%）。拜玛林制药同比增速更快（17.0% vs -94.4%）。拜玛林制药自由现金流更多（$58.9M vs $-2.8M）
BioLineRx（简称BioLine）是一家专注于药物开发的上市企业，总部设立于以色列，公司股份同时在美国纳斯达克资本市场和以色列特拉维夫证券交易所挂牌交易。
拜玛林制药是总部位于美国加利福尼亚州圣拉斐尔的生物技术企业，在美洲、亚洲、欧洲多地设有办事机构及生产设施，核心业务聚焦酶替代疗法研发，是全球首个推出Ⅰ型粘多糖贮积症治疗药物拉罗尼酶及苯丙酮尿症治疗药物的企业。
BLRX vs BMRN — 直观对比
营收规模更大
BMRN
是对方的2876.9倍
$304.0K
营收增速更快
BMRN
高出111.4%
-94.4%
净利率更高
BMRN
高出1290.7%
-1296.1%
自由现金流更多
BMRN
多$61.7M
$-2.8M
损益表 — Q2 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $304.0K | $874.6M |
| 净利润 | $-3.9M | $-46.6M |
| 毛利率 | 76.3% | 68.5% |
| 营业利润率 | -757.6% | -5.1% |
| 净利率 | -1296.1% | -5.3% |
| 营收同比 | -94.4% | 17.0% |
| 净利润同比 | -914.0% | -137.3% |
| 每股收益（稀释后） | $0.00 | $-0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BLRXBMRN
| Q4 25 | — | $874.6M | ||
| Q3 25 | — | $776.1M | ||
| Q2 25 | $304.0K | $825.4M | ||
| Q1 25 | — | $745.1M | ||
| Q4 24 | — | $747.3M | ||
| Q3 24 | — | $745.7M | ||
| Q2 24 | $5.4M | $712.0M | ||
| Q1 24 | — | $648.8M |
净利润BLRXBMRN
| Q4 25 | — | $-46.6M | ||
| Q3 25 | — | $-30.7M | ||
| Q2 25 | $-3.9M | $240.5M | ||
| Q1 25 | — | $185.7M | ||
| Q4 24 | — | $124.9M | ||
| Q3 24 | — | $106.1M | ||
| Q2 24 | $484.0K | $107.2M | ||
| Q1 24 | — | $88.7M |
毛利率BLRXBMRN
| Q4 25 | — | 68.5% | ||
| Q3 25 | — | 82.0% | ||
| Q2 25 | 76.3% | 81.8% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 81.8% | ||
| Q3 24 | — | 74.7% | ||
| Q2 24 | 83.4% | 81.7% | ||
| Q1 24 | — | 80.7% |
营业利润率BLRXBMRN
| Q4 25 | — | -5.1% | ||
| Q3 25 | — | -6.0% | ||
| Q2 25 | -757.6% | 33.5% | ||
| Q1 25 | — | 30.0% | ||
| Q4 24 | — | 21.6% | ||
| Q3 24 | — | 15.3% | ||
| Q2 24 | -107.0% | 16.9% | ||
| Q1 24 | — | 13.6% |
净利率BLRXBMRN
| Q4 25 | — | -5.3% | ||
| Q3 25 | — | -4.0% | ||
| Q2 25 | -1296.1% | 29.1% | ||
| Q1 25 | — | 24.9% | ||
| Q4 24 | — | 16.7% | ||
| Q3 24 | — | 14.2% | ||
| Q2 24 | 9.0% | 15.1% | ||
| Q1 24 | — | 13.7% |
每股收益（稀释后）BLRXBMRN
| Q4 25 | — | $-0.22 | ||
| Q3 25 | — | $-0.16 | ||
| Q2 25 | $0.00 | $1.23 | ||
| Q1 25 | — | $0.95 | ||
| Q4 24 | — | $0.65 | ||
| Q3 24 | — | $0.55 | ||
| Q2 24 | $0.00 | $0.55 | ||
| Q1 24 | — | $0.46 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $7.2M | $1.3B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $20.1M | $6.1B |
| 总资产 | $43.3M | $7.6B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BLRXBMRN
| Q4 25 | — | $1.3B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | $7.2M | $1.2B | ||
| Q1 25 | — | $1.0B | ||
| Q4 24 | — | $942.8M | ||
| Q3 24 | — | $675.4M | ||
| Q2 24 | $9.6M | $972.1M | ||
| Q1 24 | — | $747.0M |
股东权益BLRXBMRN
| Q4 25 | — | $6.1B | ||
| Q3 25 | — | $6.1B | ||
| Q2 25 | $20.1M | $6.0B | ||
| Q1 25 | — | $5.8B | ||
| Q4 24 | — | $5.7B | ||
| Q3 24 | — | $5.4B | ||
| Q2 24 | $13.9M | $5.3B | ||
| Q1 24 | — | $5.1B |
总资产BLRXBMRN
| Q4 25 | — | $7.6B | ||
| Q3 25 | — | $7.6B | ||
| Q2 25 | $43.3M | $7.5B | ||
| Q1 25 | — | $7.1B | ||
| Q4 24 | — | $7.0B | ||
| Q3 24 | — | $6.9B | ||
| Q2 24 | $64.6M | $7.1B | ||
| Q1 24 | — | $6.9B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-2.8M | $99.6M |
| 自由现金流经营现金流 - 资本支出 | $-2.8M | $58.9M |
| 自由现金流率自由现金流/营收 | -914.1% | 6.7% |
| 资本支出强度资本支出/营收 | 3.6% | 4.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $725.0M |
8季度趋势，按日历期对齐
经营现金流BLRXBMRN
| Q4 25 | — | $99.6M | ||
| Q3 25 | — | $368.7M | ||
| Q2 25 | $-2.8M | $185.3M | ||
| Q1 25 | — | $174.4M | ||
| Q4 24 | — | $185.6M | ||
| Q3 24 | — | $221.5M | ||
| Q2 24 | $-25.4M | $118.8M | ||
| Q1 24 | — | $47.0M |
自由现金流BLRXBMRN
| Q4 25 | — | $58.9M | ||
| Q3 25 | — | $340.2M | ||
| Q2 25 | $-2.8M | $168.2M | ||
| Q1 25 | — | $157.6M | ||
| Q4 24 | — | $166.1M | ||
| Q3 24 | — | $203.0M | ||
| Q2 24 | $-25.5M | $97.4M | ||
| Q1 24 | — | $20.9M |
自由现金流率BLRXBMRN
| Q4 25 | — | 6.7% | ||
| Q3 25 | — | 43.8% | ||
| Q2 25 | -914.1% | 20.4% | ||
| Q1 25 | — | 21.2% | ||
| Q4 24 | — | 22.2% | ||
| Q3 24 | — | 27.2% | ||
| Q2 24 | -472.8% | 13.7% | ||
| Q1 24 | — | 3.2% |
资本支出强度BLRXBMRN
| Q4 25 | — | 4.7% | ||
| Q3 25 | — | 3.7% | ||
| Q2 25 | 3.6% | 2.1% | ||
| Q1 25 | — | 2.3% | ||
| Q4 24 | — | 2.6% | ||
| Q3 24 | — | 2.5% | ||
| Q2 24 | 1.1% | 3.0% | ||
| Q1 24 | — | 4.0% |
现金转化率BLRXBMRN
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.94× | ||
| Q4 24 | — | 1.49× | ||
| Q3 24 | — | 2.09× | ||
| Q2 24 | -52.56× | 1.11× | ||
| Q1 24 | — | 0.53× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BLRX
暂无分部数据
BMRN
| VOXZOGO | $273.4M | 31% |
| VIMIZIM | $205.5M | 24% |
| PALYNZIQ | $125.3M | 14% |
| NAGLAZYME | $120.2M | 14% |
| Other | $49.4M | 6% |
| ALDURAZYME | $49.4M | 6% |
| KUVAN | $23.3M | 3% |
| Royalty And Other | $15.2M | 2% |
| ROCTAVIAN | $12.8M | 1% |
